On the basis of clinical risk factors, we created a new classification and divided lower grade gliomas into IDH1-WT, IDH1-MUT and ACAA2 high, and IDH1-MUT and ACAA2 low types. This evidence concerns the gene ACAA2 and central nervous system cancer.